[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558894":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":10,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo blood sample collection, glucose testing, DEXA scan to measure body composition, complete a questionnaire and have their medical records reviewed on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Non-Interventional Study",[9],[19],{"name":20,"affiliation":21,"role":22},"Kalpana Muthusamy, MBBS, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[30],{"facility":21,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Rochester","Minnesota","55905","United States",{"type":37,"coordinates":38},"Point",[39,40],-92.4699,44.02163,{"lat":40,"lon":39},[43,44],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":20,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100558894",false,"NCT06557057","Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk","Inclusion Criteria:\n\n* Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or with other high risk breast conditions. Post-menopause will be defined as women who experience 12 months of amenorrhea or have undergone bilateral salpingo-oophorectomy.\n\n  * 25 women who are planning to start or are within 6 months of starting treatment with aromatase inhibitors, after consultation in breast clinic and cancer center.\n  * 25 women who will be starting Tamoxifen (comparative group)\n  * 25 healthy post menopausal women will also be recruited.\n\nExclusion Criteria:\n\n* Established diagnosis of diabetes\n* Therapy with medications that could affect glucose metabolism\n* Screening fasting glucose ≥ 126 mg\u002Fdl, and\u002For HbA1c ≥ 6.5%\n* History of upper GI surgery that alters gastric emptying or causing malabsorption e.g., bariatric surgery, fundoplication",true,"FEMALE",{"count":55,"type":56},66,"ESTIMATED","OBSERVATIONAL","This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.",[60],"HER2-Positive Breast Carcinoma","2026-03-26",{"date":63,"type":64},"2026-03-31","ACTUAL",{"date":66,"type":64},"2023-11-16",{"date":68,"type":56},"2026-12-01",{"name":5,"class":6},1]